ClinicalTrials.gg
Not yet recruitingNCT07938073Updated Nov 16, 2026

Phase 2 Study Of IDH 1/2 Inhibitor Vorasidenib In Patients With IDH2-Mutated Intrahepatic Cholangiocarcinoma

A Phase 2 interventional study of Vorasidenib in IDH2-Mutated Intrahepatic Cholangiocarcinoma, sponsored by M.D. Anderson Cancer Center. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by M.D. Anderson Cancer Center · Phase 2, Interventional, and Treatment

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
26
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 13 studies in Cholangiocarcinoma by M.D. Anderson Cancer Center — 5 open to participants now, 7 under way, none of them phase 3. Cholangiocarcinoma · M.D. Anderson Cancer Center.

Planned enrollment
6th of 12
26 · median 26
Started
2027
the only one that year
Phase 2
5 of 13
3 open now
Registered
13th of 13
by date

Among the 13 studies in Cholangiocarcinoma by M.D. Anderson Cancer Center, this one is the 6th largest by planned enrollment of the 12 interventional ones that give a count, is the only one that started in 2027, is one of 5 in phase 2, and was the 13th registered.

Cholangiocarcinoma

825 studies on the registry are indexed under Cholangiocarcinoma; 287 are open to participants now.

Browse Cholangiocarcinoma studies →

Open to participants now

5 of the 13 studies in Cholangiocarcinoma by M.D. Anderson Cancer Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 211 Cholangiocarcinoma studies recruiting now, 141 (67%) set no upper age limit and 49 (23%) stop at 75 or younger; 10 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Cholangiocarcinoma by M.D. Anderson Cancer Center, or all of them as a file.
02

Study summary

To find the recommended dose of vorasidenib that can be given to participants with IDH2-mutated iCCA.

Read the detailed description

Primary Objectives and Endpoints To evaluate the safety and efficacy of vorasidenib in participants with IDH2-mutated iCCA.

Primary endpoints for the study will be the evaluation of dose-limiting toxicities (DLTs) and landmark progression-free survival (PFS).

03

Conditions studied

  • IDH2-Mutated Intrahepatic Cholangiocarcinoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Eligibility Criteria

  1. Patients with diagnosis of unresectable or iCCA (confirmed by treating clinician) who have received at least one standard of care systemic therapy for iCCA.
  2. Patients must have received a standard first-line therapy (as per NCCN guidelines) for cholangiocarcinoma/ biliary cancer
  3. Presence of an IDH2 mutation confirmed by laboratory testing using validated methods, such as polymerase chain reaction (PCR) or next-generation sequencing (NGS).
  4. Patients must have , defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as ≥20 mm (≥2 cm) by chest x-ray or as ≥10 mm (≥1 cm) with CT scan, MRI, or calipers by clinical exam.
  5. Age ≥18 years.
  6. performance status ≤2 ( ≥60%,).
  7. Patients must have adequate organ and marrow function as defined below:

    • ≥1,000/mcL
    • ≥75,000/mcL
    • total ≤ 1.5 x institutional (ULN)
    • (SGOT)/ALT(SGPT) ≤2.5 × institutional ULN
    • Creatinine ≤ institutional ULN
  8. For Participants with evidence of chronic virus (HBV) infection, the HBV viral load must be undetectable
  9. Participants with a history of virus (HCV) infection must have been treated and cured. For Participants with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.
  10. Participants with a prior or concurrent whose natural history or treatment does not interfere with the safety or efficacy assessment of the regimen are eligible for this trial.
  11. Participants with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the Functional Classification. To be eligible for this trial, Participants should be class 2B or better.
  12. The effects of vorasidenib on the developing human fetus are unknown. For this reason, women of and men must agree to use adequate (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. (Refer to Pregnancy Assessment Policy MD Anderson Institutional Policy # CLN1114). This includes all female patients, between the onset of menses (as early as 8 years of age) and 55 years unless the patient presents with an applicable exclusionary factor which may be one of the following:

    • (no menses in greater than or equal to 12 consecutive months).
    • History of hysterectomy or bilateral salpingo-oophorectomy.
    • Ovarian failure (Follicle Stimulating Hormone and Estradiol in menopausal range, who have received Whole Pelvic Radiation Therapy).
    • History of bilateral tubal ligation or another surgical sterilization procedure.
  13. Approved methods of birth control are as follows: Hormonal contraception (i.e. birth control pills, injection, implant, transdermal patch, vaginal ring), Intrauterine device (IUD), Tubal Ligation or hysterectomy, Subject/Partner post vasectomy, Implantable or injectable contraceptives, and condoms plus spermicide. Not engaging in sexual activity for the total duration of the trial and the drug is an acceptable practice; however periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of birth control. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.
  14. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study and not donate sperm for the duration of study participation, and 4 months after completion of vorasidenib administration.
  15. Ability to understand and the willingness to sign a written document.

Exclusion Criteria

  1. Prior treatment with an IDH inhibitor.
  2. Participants who have had chemotherapy or radiotherapy within 3 weeks prior to entering the study.
  3. Participants who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > Grade 2 with the exception of alopecia.
  4. Participants who are receiving any other investigational agents.
  5. Concomitant use of strong inducers or inhibitors, or medications with potential for significant drug-drug interactions with vorasidenib as detailed in the prescribing information (https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf).
  6. Participants with active . The investigator(s) must state a medical or scientific reason if Participants who have brain metastases will be excluded from the study.
  7. History of allergic reactions attributed to compounds of similar chemical or biologic composition to [list out Agent(s)] or other agents used in study.
  8. Examples of such agents or substances include those that interact through the CYP450 isoenzyme system or other sources of drug interactions (e.g., P-glycoprotein). Specifically excluded substances may be listed below and presented as an appendix. If appropriate, the following text concerning CYP450 interactions may be used or modified.

    Note: This must account for all agents to be used in this study, including commercial agents. Please refer to the FDA product labels for all commercial agents and include information on prohibited concomitant medications in all applicable sections of the protocol.

  9. Participants with uncontrolled intercurrent illness (Indicate clearly what type or extent)
  10. (HIV)-infected Participants are excluded, except those on effective ART with undetectable viral load, who are eligible.
  11. Participants with psychiatric illness/social situations that would limit compliance with study requirements.
  12. Pregnant women are excluded from this study because vorasidenib is agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with vorasidenib, breastfeeding should be discontinued if the mother is treated with vorasidenib. These potential risks may also apply to other agents used in this study.
  13. The investigator(s) must state a medical or scientific reason if Participants who are cancer survivors will be excluded from the study.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
26 participants (estimated)

Study arms

  • Experimental
    Safety Run-In/Expansion

    Treatment with Vorasidenib (PO) Q4W

    Drug: Vorasidenib

Interventions

06

What researchers measure

Primary outcomes

  1. Safety and adverse events (AEs

    Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 6.0

    Time frame: Through study completion; an average of 1 year.

07

Study locations

1 site
08

References and documents

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2027; primary completion for Jan 2029, 20 months later.

Of 147 non-industry phase 2 interventional studies under Cholangiocarcinoma, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 65. This study's planned 20 months is below that.

Counting every sponsor, half of 173 studies reached it within 46 months; a quarter within 29 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2026
First posted
Nov 16, 2026
StartEst.
Apr 29, 2027
Primary completionEst.
Jan 1, 2029
CompletionEst.
Jan 1, 2031
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07938073
Collaborators
Servier Pharmaceuticals, LLC
Responsible party
Sponsor
First posted
Nov 16, 2026
Start date
Apr 29, 2027 (estimated)
Primary completion
Jan 1, 2029 (estimated)
Completion
Jan 1, 2031 (estimated)
Last update
Nov 16, 2026

Study contacts

Milind Javle, MD
Contact
mjavle@mdanderson.org
713-792-5434
Milind Javle, MD
principal investigator · UT MD Anderson Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vorasidenib

Start the discussion